New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 11, 2012
17:23 EDTIDRAIdera Pharmaceuticals files to sell 16.98M shares of common stock for holders
News For IDRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
07:37 EDTIDRAStifel to hold a conference
Subscribe for More Information
November 7, 2014
07:19 EDTIDRAIdera Pharmaceuticals to expand rare disease development portfolio
Idera Pharmaceuticals announced plans to collaborate with Parent Project Muscular Dystrophy, or PPMD, to develop a potential non-steroid-based anti-inflammatory treatment using Idera's Toll-like receptor, or TLR, antagonism technology. DMD is a rare, fatal muscle disorder affecting approximately 15,000-20,000 patients in the U.S. It is characterized by progressive muscle weakness, pulmonary and cardiac dysfunction, and death typically before age 30. Previously published independent research has shown that TLR 7 is up-regulated in DMD patients.1 In a preclinical model of DMD, knockout of the gene for the MYD88 TLR adaptor protein led to significant improvements in skeletal and cardiac muscle function. In a separate study conducted by researchers from Children's National Health System and Idera, treatment with a TLR antagonist candidate led to a significant reduction of pro-inflammatory cytokines, a significant decrease in creatine kinase, and a significant increase in muscle strength in a preclinical DMD model.2 Idera plans to collaborate with PPMD to expand preclinical studies and develop a clinical development strategy for a TLR antagonist candidate in DMD.
07:15 EDTIDRAIdera Pharmaceuticals reports Q3 EPS (11c), consensus (11c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use